Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability

Jacqueline C. Barrientos, MD, Nina D. Wagner-Johnston, MD, Sven De Vos, MD, PhD, Steven E. Coutre, MD, Marshall T. Schreeder, MD, MPH, Ian Flinn, MD, PhD, Jeff P. Sharman, MD, Kanti R. Rai, MD, John P. Leonard, M.D., Roger Dansey, MD, Yeonhee Kim, PhD, Leanne M. Holes, Henry Adewoye, MD, Richard R. Furman, MD

Blood (2013) 122 (21): 4176.

https://doi.org/10.1182/blood.V122.21.4176.4176

Published: 2013

Journal Articles

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Blood (2013) 122 (21): 1632.

https://doi.org/10.1182/blood.V122.21.1632.1632

Published: 2013

Journal Articles

A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, MD, Sven De Vos, MD, PhD, John P. Leonard, MD, Jacqueline C. Barrientos, MD, Marshall T. Schreeder, MD, Ian W. Flinn, MD, PhD, Jeff P. Sharman, MD, Thomas Boyd, MD, Nathan Fowler, MD, Kanti R. Rai, MD, Yeonhee Kim, PhD, Leanne M. Holes, Roger Dansey, MD, Thomas M. Jahn, MD, PhD, Steven E. Coutre, MD

Blood (2013) 122 (21): 4180.

https://doi.org/10.1182/blood.V122.21.4180.4180

Published: 2013

Journal Articles

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Sarah A Meadows, Huong (Marie) Nguyen, M.D., Christophe Queva, PhD, Brian J. Lannutti, PhD, Adam Kashishian, Susie Jun, MD, PhD, Steven E. Coutre, MD, Roger Dansey, MD, Jason Gotlib, MD, MS

Blood (2013) 122 (21): 4065.

https://doi.org/10.1182/blood.V122.21.4065.4065

Published: 2013

Journal Articles

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Sven De Vos, MD, PhD, Richard R. Furman, MD, Jacqueline C. Barrientos, MD, Nina D. Wagner-Johnston, MD, Ian Flinn, MD, PhD, Jeff P. Sharman, MD, Thomas Boyd, MD, John P. Leonard, M.D., Roger Dansey, MD, Yeonhee Kim, PhD, Leanne M. Holes, Ronald L. Dubowy, MD, Steven E. Coutre, MD

Blood (2013) 122 (21): 2878.

https://doi.org/10.1182/blood.V122.21.2878.2878

Published: 2013

Journal Articles

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Feng Jin, PhD, Huafeng Zhou, PhD, Lorna Fang, Xiaoming Li, PhD, Terry Newcomb, MD, Roger Dansey, MD, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5054.

https://doi.org/10.1182/blood.V122.21.5054.5054

Published: 2013

Journal Articles

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Blood (2013) 122 (21): 85.

https://doi.org/10.1182/blood.V122.21.85.85

Published: 2013

Journal Articles

Patients with Non-Hodgkin’s Lymphoma Receiving Myelosuppressive Chemotherapy with First and Subsequent Cycle Pegfilgrastim Support Experience Low Rates of Neutropenic Complications: Preliminary Results of FIRST, a Prospective Community-Based Study.

Howard Ozer, MD, PhD, Stephen J. Noga, MD, PhD, Vicki A. Morrison, MD, Beiying Ding, PhD, Roger Dansey, MD

Blood (2005) 106 (11): 4705.

https://doi.org/10.1182/blood.V106.11.4705.4705

Published: 2005

Journal Articles

First-Cycle Pegfilgrastim Reduces Chemotherapy-Induced Febrile Neutropenia among Older Patients with NHL Treated in Community Practice: Results from a Large, Randomized, Controlled Trial.

William Ershler, MD, Jennifer Tam, Veena Charu, MD, Ali Ben-Jacob, MD, Seta Shahin, Jeannette Green, Roger Dansey, MD, Lodovico Balducci, MD

Blood (2005) 106 (11): 4286.

https://doi.org/10.1182/blood.V106.11.4286.4286

Published: 2005

Journal Articles

Pegfilgrastim (Neulasta®) and Filgrastim (Neupogen®) Use in Patients Receiving Chemotherapy in Oncology Practices: Interim Results of the Assessment of Current CSF Evaluation for Proper Therapy (ACCEPT) Study.

Luis Alberto Meza, MD, Veena Charu, MD, Roger Dansey, MD, Fang Xie, PhD, Bradley Stolshek, PharmD

Blood (2004) 104 (11): 5309.

https://doi.org/10.1182/blood.V104.11.5309.5309

Published: 2004

Journal Articles

Safety of Low Dose Enoxaparin in Thrombocytopenic Hematopoeitic Stem Cell Recepients: A Single Institution’a Case Series.

Rami B. Ibrahim, Pharm.D., Nikki Milan, Pharm.D., Edward Peres, M.D., Muneer H. Abidi, M.D., Roger Dansey, M.D., Esteban M. Abella, M.D., Lance K. Heilbrun, Ph.D., Jared Klein, M.D.

Blood (2004) 104 (11): 4090.

https://doi.org/10.1182/blood.V104.11.4090.4090

Published: 2004

Journal Articles

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

Peter A. McSweeney, Richard A. Nash, Keith M. Sullivan, Jan Storek, Leslie J. Crofford, Roger Dansey, Maureen D. Mayes, Kevin T. McDonagh, J. Lee Nelson, Theodore A. Gooley, Leona A. Holmberg, C. S. Chen, Mark H. Wener, Katherine Ryan, Julie Sunderhaus, Ken Russell, John Rambharose, Rainer Storb, Daniel E. Furst

Blood (2002) 100 (5): 1602–1610.

https://doi.org/10.1182/blood.V100.5.1602.h81702001602_1602_1610

Published: 2002

NARROW

Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Patients with Non-Hodgkin’s Lymphoma Receiving Myelosuppressive Chemotherapy with First and Subsequent Cycle Pegfilgrastim Support Experience Low Rates of Neutropenic Complications: Preliminary Results of FIRST, a Prospective Community-Based Study.

First-Cycle Pegfilgrastim Reduces Chemotherapy-Induced Febrile Neutropenia among Older Patients with NHL Treated in Community Practice: Results from a Large, Randomized, Controlled Trial.

Pegfilgrastim (Neulasta®) and Filgrastim (Neupogen®) Use in Patients Receiving Chemotherapy in Oncology Practices: Interim Results of the Assessment of Current CSF Evaluation for Proper Therapy (ACCEPT) Study.

Safety of Low Dose Enoxaparin in Thrombocytopenic Hematopoeitic Stem Cell Recepients: A Single Institution’a Case Series.

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only